DMB Acquisition, formerly LifeSci Acquisition III, gave notice to the SEC that its is withdrawing an offering of 7.5 million units initially registered in July 2021.
The SPAC had planned to target companies in North America or Europe that are developing assets in the biopharma, medical technology, digital health, and healthcare services sectors.
DMB is led by CEO and Director Andrew McDonald, who was chairman and CEO of LifeSci Acquisition until it closed its business combination with Vincera Pharma in December 2020.
The SPAC had been expected to apply for a Nasdaq listing with LifeSci Capital and Ladenburg Thalmann serving as joint book-running managers. Read more.
